tweetindex
DE

Sumanta K. Pal, MD, FASCO ✓

@montypal · Los Angeles, CA · joined 16 Mar 2009

@cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.

23 098Followers
4 337Following
31 599Posts total
44.3KViews on collected posts

Neueste Beiträge

A simply brilliant meeting - #NorCalGU26 - hosted by #DrMamtaParikh & @ADESAIONCMD. Kicking off the day with a brilliant #prostatecancer session with @mdallera & @DivyaParikhMD including experts from @KPSCalResearch, @UCSFCancer, @UCD_Cancer & @StanfordCancer. Honored to deliver
928 views · 18 likes · 9 reposts · 1 replies Open on X →
Had the chance to sit down with @wolchokj, a pioneering investigator in #melanoma. A marvelous opportunity to discuss an evolution from dismal days when chemotherapy was the prevailing option to the tidal wave of novel CPIs, TILs & most recently #personalized #vaccines that are 1.6K views · 25 likes · 7 reposts · 2 replies Open on X →
Thanks @SuyogCancer for sharing this important slide. I'm confident we can work towards overcoming at least some of this. Excited to work with @VanitaNoronha, @DrAmitJoshi_TMC, @batraatulonc, @Nilanchali1 & all others interested to bridge the gap. The amount of 1.8K views · 14 likes · 5 reposts · 1 replies Open on X →
Looking forward to a terrific meeting! Come join us for some terrific sessions with speakers including @arkhaki @Stanford, @JCohenMD @cityofhopeoc, @riess_md @UCD_Cancer, @MNagasaka @UCIrvineHealth, @AdityaSunavs @cityofhope, @TDorffOnc @cityofhope, @allisonkurian @Stanford & 1.5K views · 15 likes · 8 reposts · 0 replies Open on X →
Join us at the Precision Oncology Symposium presented by @ANCO_News & @MOASC_Office on Nov. 7, 2026, in San Francisco! Discover how advances in tumor profiling, molecular diagnostics, and targeted therapies are transforming personalized cancer care and improving patient outcomes.
1.8K views · 4 likes · 1 reposts · 0 replies Open on X →
Reasons for not to do research In LMICs Great slide by @VanitaNoronha . We need to overcome all these to do great research especially it u r from LMICs . And it is possible 👍 @SirohiBhawna @BalcoMedical @oncology_bg https://t.co/HLZN832BI5
5.1K views · 55 likes · 11 reposts · 2 replies Open on X →
🎙 @montypal of @cityofhope and pioneering investigator Dr. Jedd Wolchok of @WeillCornell discuss the remarkable evolution in melanoma treatments on the latest episode of the #ASCODailyNews Podcast: https://t.co/NriZEaUd3C https://t.co/yhbTHYHSiA
4.6K views · 9 likes · 2 reposts · 1 replies Open on X →
@montypal @kor_shah @SalvadorjcMD @ruchi1agarwal @JAMANetworkOpen @UroDocAsh @PGrivasMDPhD @neerajaiims @gbanna74 @ravikanesvaran @shilpaonc @ASCO @UroOnc @AlisonBirtle @OncoBellmunt An all-star team and spectacular work. Really enjoyed reading through the article! @montypal @kor 80 views · 3 likes · 0 reposts · 0 replies Open on X →
@montypal @kor_shah @SalvadorjcMD @ruchi1agarwal @JAMANetworkOpen @UroDocAsh @PGrivasMDPhD @neerajaiims @gbanna74 @ravikanesvaran @shilpaonc @ASCO @UroOnc @AlisonBirtle @OncoBellmunt Misalignment Between Clinical Trial Access and Disease Burden in US Bladder Cancer - Sumanta Pal
95 views · 3 likes · 0 reposts · 0 replies Open on X →
@montypal @kor_shah @SalvadorjcMD @ruchi1agarwal @JAMANetworkOpen @UroDocAsh @PGrivasMDPhD @neerajaiims @gbanna74 @ravikanesvaran @shilpaonc @ASCO @UroOnc @AlisonBirtle @OncoBellmunt Congratulations to the whole team. Trials clustering where social vulnerability is lowest rather 101 views · 3 likes · 0 reposts · 0 replies Open on X →
Tremendous work from a team led by @kor_shah @SalvadorjcMD & @ruchi1agarwal, co-first authors on this piece in @JAMANetworkOpen highlighting the regional variations in #bladdercancer trials in the US. Their detailed analysis of regional variations in study availability points to
11K views · 57 likes · 17 reposts · 4 replies Open on X →
Our study is now published in @JAMANetworkOpen! We mapped 436 bladder cancer clinical trials across US counties and examined associations with incidence, mortality, & social vulnerability. Among 3,145 US counties, 77.3% had no bladder cancer trials! 🧵⬇️ https://t.co/8HWU1Lpq2b 15.8K views · 68 likes · 22 reposts · 7 replies Open on X →
Tx @drenriquegrande! I was nervous. @Eminem said "U've only got 1 shot!" & that's true for the @myESMO Prez sesh; didn't want to disappoint @peters_solange @FAndreMD @CharlesSwanton & #ESMO22 audience. I'm no authority on the discussant role but heres my tips 4 trainees; plz add!
0 views · 468 likes · 118 reposts · 33 replies Open on X →
🗣️If you are a fellow, oncologist or work in the pharma industry and want to improve your oral communication skills and make effective presentations, you just have to watch @montypal #ESMO22 presidential session discussion on loop. 🎩Hats off!! @OncoAlert https://t.co/tvPGyKHYqd
0 views · 345 likes · 49 reposts · 8 replies Open on X →

Im Vergleich zu Konten gleicher Größe

12 Beiträge aus den letzten 90 Tagen, verglichen mit der Größenklasse 10K–100K Follower. wird mehr Menschen gezeigt als Konten gleicher Größe.

Medianaufrufe1 665dieses Konto924Median für 10K–100K
Reichweite, %7.21%dieses Konto3.62%Median für 10K–100K
Interaktion, %1.46%dieses Konto1.52%Median für 10K–100K
KennzahlDieses KontoMedian für 10K–100KVerhältnis
Medianaufrufe pro Beitrag1 6659241.80×
Reichweite (Aufrufe ÷ Follower)7.21%3.62%1.99×
Interaktionsrate1.46%1.52%0.96×

Weitere Konten dieser Größe →   Mit einem anderen Konto vergleichen →   Wie diese Vergleichswerte entstehen →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

15.8K3 Sep
11K7 Sep
101
959 Sep
80
4.6K10 Sep
5.1K18 Sep
1.8K
1.5K19 Sep
1.8K
1.6K
928

Last 12 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.64%3 Sep
0.75%7 Sep
2.97%
3.16%9 Sep
3.75%
0.30%10 Sep
1.38%18 Sep
0.34%
1.54%19 Sep
1.13%
2.19%
3.02%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes66.8%274 in total
Reposts20.0%82 in total
Replies4.4%18 in total
Quotes3.2%13 in total
Bookmarks5.6%23 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

Followers by day

16 Sep

Daily snapshots since 16 Sep 2026; the dashed line is the starting count.

Ähnliche Konten